Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oralvac is a sublingual immunotherapy (SLIT) product designed to treat severe allergies such as allergic rhinitis caused by house dust mite, tree pollen (including birch, alder, hazel, olive, cypress), grass pollen (including rye and B2 grasses), weed pollen and moulds[2][7]. It contains standardized aqueous allergen extracts in glycerol at various concentrations. The treatment works by modulating the immune response to specific allergens through repeated exposure via daily drops administered under the tongue. This approach aims to desensitize the immune system over time and reduce allergic symptoms when other medications have not been effective[1][3][5]. The therapy typically involves an initial up-dosing phase followed by a maintenance phase lasting several months or years. Clinical studies report good efficacy and tolerability with mostly mild local side effects such as oral itching or swelling[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oralvac.